In 33 pretreated patients with KRAS-mutant NSCLC, sotorasib was combined with two different doses of afatinib (20 mg in cohort one and 30 mg in cohort two), showing respectively an ORR of 20% and 35% and a DCR of 70% and 74%; the most common grade 3 AE was diarrhea. Here, KRAS is linked to non-small cell lung carcinoma.